Centessa Pharmaceuticals (NASDAQ:CNTA – Get Rating)‘s stock had its “outperform” rating reissued by SVB Leerink in a research report issued to clients and investors on Friday, MarketBeat.com reports. They presently have a $6.00 price objective on the stock. SVB Leerink’s price objective suggests a potential upside of 50.38% from the stock’s current price.
Other research analysts have also issued reports about the stock. Morgan Stanley decreased their price objective on shares of Centessa Pharmaceuticals from $5.00 to $4.00 and set an “underweight” rating for the company in a report on Tuesday, January 24th. SVB Securities initiated coverage on Centessa Pharmaceuticals in a report on Friday, March 17th. They issued an “outperform” rating and a $6.00 target price for the company. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $5.83.
Centessa Pharmaceuticals Stock Up 1.0 %
NASDAQ:CNTA traded up $0.04 during midday trading on Friday, hitting $3.99. The company had a trading volume of 484 shares, compared to its average volume of 171,171. The company has a quick ratio of 12.49, a current ratio of 12.49 and a debt-to-equity ratio of 0.18. The stock’s fifty day moving average price is $3.68 and its 200-day moving average price is $3.77. Centessa Pharmaceuticals has a 52-week low of $2.88 and a 52-week high of $9.95.
Institutional Trading of Centessa Pharmaceuticals
About Centessa Pharmaceuticals
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; and SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B.
- Get a free copy of the StockNews.com research report on Centessa Pharmaceuticals (CNTA)
- Nike, Inc’s Q3 Surprise Isn’t All That Surprising: Is It A Buy?
- Want Diversified Upside in Biotechnology? Check out LABU
- 3 Tech Stocks Well Positioned For Growth At A Reasonable Price
- These 3 Dividend Growers Yield More Than the 10-Year Note
- Be Cautious of Valens Semiconductor Analyst Estimates
Receive News & Ratings for Centessa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Centessa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.